

# Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/CC2FEA5C4A2CEN.html>

Date: March 2022

Pages: 64

Price: US\$ 3,250.00 (Single User License)

ID: CC2FEA5C4A2CEN

## Abstracts

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune motor sensory peripheral neuropathy with chronic demyelination of the proximal peripheral nerves as the main lesion. It belongs to chronic acquired demyelinating multiple neuropathy (ADP), the most common type of CADP, and presents a course of chronic progression or remission - recurrence.

This report contains market size and forecasts of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Global, including the following market information:

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Corticosteroid Therapy Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Chronic Inflammatory Demyelinating Polyneuropathy

(CIDP) include Teijin Pharma, Shire, Pfizer, Octapharma, Momenta Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Kedrion, Grifols and CSL Behring (CSL Limited), etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segment Percentages, by Type, 2021 (%)

Corticosteroid Therapy

IVIG Treatment

Plasma Exchange Therapy

Immunosuppressive Drug Therapy

Immunomodulator Therapy

Other

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segment Percentages, by Application, 2021 (%)

Hospital

Specialist Neurology Clinic

Research and Academic Laboratories

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

## Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Teijin Pharma

Shire

Pfizer

Octapharma

Momenta Pharmaceuticals

Mitsubishi Tanabe Pharma Corporation

Kedrion

Grifols

CSL Behring (CSL Limited)

Bio Products Laboratory

Baxter

MedDay Pharmaceuticals

GeNeuro Pharmaceuticals

## Contents

### **1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS**

- 1.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Definition
- 1.2 Market Segments
  - 1.2.1 Market by Type
  - 1.2.2 Market by Application
- 1.3 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
  - 1.5.1 Research Methodology
  - 1.5.2 Research Process
  - 1.5.3 Base Year
  - 1.5.4 Report Assumptions & Caveats

### **2 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) OVERALL MARKET SIZE**

- 2.1 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size: 2021 VS 2028
- 2.2 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
  - 2.3.1 Market Opportunities & Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Restraints

### **3 COMPANY LANDSCAPE**

- 3.1 Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players in Global Market
- 3.2 Top Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies Ranked by Revenue
- 3.3 Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Companies
- 3.4 Top 3 and Top 5 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies in Global Market, by Revenue in 2021

3.5 Global Companies Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)  
Product Type

3.6 Tier 1, Tier 2 and Tier 3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players in Global Market

3.6.1 List of Global Tier 1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies

3.6.2 List of Global Tier 2 and Tier 3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies

## **4 MARKET SIGHTS BY PRODUCT**

4.1 Overview

4.1.1 by Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Markets, 2021 & 2028

4.1.2 Corticosteroid Therapy

4.1.3 IVIG Treatment

4.1.4 Plasma Exchange Therapy

4.1.5 Immunosuppressive Drug Therapy

4.1.6 Immunomodulator Therapy

4.1.7 Other

4.2 By Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue & Forecasts

4.2.1 By Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2022

4.2.2 By Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2023-2028

4.2.3 By Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028

## **5 SIGHTS BY APPLICATION**

5.1 Overview

5.1.1 By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Specialist Neurology Clinic

5.1.4 Research and Academic Laboratories

5.2 By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue & Forecasts

5.2.1 By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2022

5.2.2 By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2023-2028

5.2.3 By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028

## **6 SIGHTS BY REGION**

6.1 By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2021 & 2028

6.2 By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue & Forecasts

6.2.1 By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2022

6.2.2 By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2023-2028

6.2.3 By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028

6.3.2 US Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.3.3 Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.3.4 Mexico Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028

6.4.2 Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.4.3 France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.4.4 U.K. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.4.5 Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028



6.4.6 Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.4.7 Nordic Countries Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.4.8 Benelux Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028

6.5.2 China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.5.3 Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.5.4 South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.5.5 Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.5.6 India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028

6.6.2 Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.6.3 Argentina Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028

6.7.2 Turkey Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.7.3 Israel Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.7.4 Saudi Arabia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

6.7.5 UAE Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size, 2017-2028

## **7 PLAYERS PROFILES**

## 7.1 Teijin Pharma

7.1.1 Teijin Pharma Corporate Summary

7.1.2 Teijin Pharma Business Overview

7.1.3 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings

7.1.4 Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)

7.1.5 Teijin Pharma Key News

## 7.2 Shire

7.2.1 Shire Corporate Summary

7.2.2 Shire Business Overview

7.2.3 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings

7.2.4 Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)

7.2.5 Shire Key News

## 7.3 Pfizer

7.3.1 Pfizer Corporate Summary

7.3.2 Pfizer Business Overview

7.3.3 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings

7.3.4 Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)

7.3.5 Pfizer Key News

## 7.4 Octapharma

7.4.1 Octapharma Corporate Summary

7.4.2 Octapharma Business Overview

7.4.3 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings

7.4.4 Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)

7.4.5 Octapharma Key News

## 7.5 Momenta Pharmaceuticals

7.5.1 Momenta Pharmaceuticals Corporate Summary

7.5.2 Momenta Pharmaceuticals Business Overview

7.5.3 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings

7.5.4 Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy

(CIDP) Revenue in Global Market (2017-2022)

7.5.5 Momenta Pharmaceuticals Key News

7.6 Mitsubishi Tanabe Pharma Corporation

7.6.1 Mitsubishi Tanabe Pharma Corporation Corporate Summary

7.6.2 Mitsubishi Tanabe Pharma Corporation Business Overview

7.6.3 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings

7.6.4 Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)

7.6.5 Mitsubishi Tanabe Pharma Corporation Key News

7.7 Kedrion

7.7.1 Kedrion Corporate Summary

7.7.2 Kedrion Business Overview

7.7.3 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings

7.7.4 Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)

7.7.5 Kedrion Key News

7.8 Grifols

7.8.1 Grifols Corporate Summary

7.8.2 Grifols Business Overview

7.8.3 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings

7.8.4 Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)

7.8.5 Grifols Key News

7.9 CSL Behring (CSL Limited)

7.9.1 CSL Behring (CSL Limited) Corporate Summary

7.9.2 CSL Behring (CSL Limited) Business Overview

7.9.3 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings

7.9.4 CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)

7.9.5 CSL Behring (CSL Limited) Key News

7.10 Bio Products Laboratory

7.10.1 Bio Products Laboratory Corporate Summary

7.10.2 Bio Products Laboratory Business Overview

7.10.3 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings

7.10.4 Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)

7.10.5 Bio Products Laboratory Key News

7.11 Baxter

7.11.1 Baxter Corporate Summary

7.11.2 Baxter Business Overview

7.11.3 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings

7.11.4 Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)

7.11.5 Baxter Key News

7.12 MedDay Pharmaceuticals

7.12.1 MedDay Pharmaceuticals Corporate Summary

7.12.2 MedDay Pharmaceuticals Business Overview

7.12.3 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings

7.12.4 MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)

7.12.5 MedDay Pharmaceuticals Key News

7.13 GeNeuro Pharmaceuticals

7.13.1 GeNeuro Pharmaceuticals Corporate Summary

7.13.2 GeNeuro Pharmaceuticals Business Overview

7.13.3 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Major Product Offerings

7.13.4 GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global Market (2017-2022)

7.13.5 GeNeuro Pharmaceuticals Key News

## **8 CONCLUSION**

## **9 APPENDIX**

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

## List Of Tables

### LIST OF TABLES

- Table 1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Opportunities & Trends in Global Market
- Table 2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Drivers in Global Market
- Table 3. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Restraints in Global Market
- Table 4. Key Players of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Global Market
- Table 5. Top Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Players in Global Market, Ranking by Revenue (2021)
- Table 6. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue by Companies, (US\$, Mn), 2017-2022
- Table 7. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Share by Companies, 2017-2022
- Table 8. Global Companies Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Type
- Table 9. List of Global Tier 1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 10. List of Global Tier 2 and Tier 3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 11. By Type – Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2021 & 2028
- Table 12. By Type - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global (US\$, Mn), 2017-2022
- Table 13. By Type - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global (US\$, Mn), 2023-2028
- Table 14. By Application – Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2021 & 2028
- Table 15. By Application - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global (US\$, Mn), 2017-2022
- Table 16. By Application - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in Global (US\$, Mn), 2023-2028
- Table 17. By Region – Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2021 & 2028
- Table 18. By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy

(CIDP) Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2023-2028

Table 30. Teijin Pharma Corporate Summary

Table 31. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings

Table 32. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US\$, Mn), (2017-2022)

Table 33. Shire Corporate Summary

Table 34. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings

Table 35. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US\$, Mn), (2017-2022)

Table 36. Pfizer Corporate Summary

Table 37. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings

Table 38. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US\$, Mn), (2017-2022)

Table 39. Octapharma Corporate Summary

Table 40. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings

Table 41. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US\$, Mn), (2017-2022)

Table 42. Momenta Pharmaceuticals Corporate Summary

Table 43. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings

Table 44. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US\$, Mn), (2017-2022)

Table 45. Mitsubishi Tanabe Pharma Corporation Corporate Summary

Table 46. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings

Table 47. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US\$, Mn), (2017-2022)

Table 48. Kedrion Corporate Summary

Table 49. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings

Table 50. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US\$, Mn), (2017-2022)

Table 51. Grifols Corporate Summary

Table 52. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings

Table 53. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US\$, Mn), (2017-2022)

Table 54. CSL Behring (CSL Limited) Corporate Summary

Table 55. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings

Table 56. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US\$, Mn), (2017-2022)

Table 57. Bio Products Laboratory Corporate Summary

Table 58. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings

Table 59. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US\$, Mn), (2017-2022)

Table 60. Baxter Corporate Summary

Table 61. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings

Table 62. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US\$, Mn), (2017-2022)

Table 63. MedDay Pharmaceuticals Corporate Summary

Table 64. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings

Table 65. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US\$, Mn), (2017-2022)

Table 66. GeNeuro Pharmaceuticals Corporate Summary

Table 67. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Product Offerings

Table 68. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue (US\$, Mn), (2017-2022)



## List Of Figures

### LIST OF FIGURES

Figure 1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Segment by Type in 2021

Figure 2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Segment by Application in 2021

Figure 3. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue in 2021

Figure 8. By Type - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028

Figure 9. By Application - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028

Figure 10. By Region - Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028

Figure 11. By Country - North America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028

Figure 12. US Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028

Figure 16. Germany Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 17. France Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028

Figure 24. China Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 28. India Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028

Figure 30. Brazil Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Market Share, 2017-2028

Figure 33. Turkey Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue, (US\$, Mn), 2017-2028

Figure 37. Teijin Pharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Shire Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue

Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Pfizer Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Octapharma Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Momenta Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Mitsubishi Tanabe Pharma Corporation Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Kedrion Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Grifols Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. CSL Behring (CSL Limited) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Bio Products Laboratory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Baxter Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. MedDay Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. GeNeuro Pharmaceuticals Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

## I would like to order

Product name: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/CC2FEA5C4A2CEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CC2FEA5C4A2CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

